Mark S. Blumenkranz is Director at Avalanche Biotechnologies, Inc. (AAVL). They have made 1 open-market trade across 1 company since 2015, most recently 2024-06-11.
CIK 0001614869
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| [AAVL] | SELL · 10b5-1 | 2015-06-11 | 2015-06-15 | $39.97 | $76K | N/A | N/A | N/A |
| [AAVL] | SELL · 10b5-1 | 2015-06-09 | 2015-06-11 | $35.86 | $828K | N/A | N/A | N/A |
| [AAVL] | SELL · 10b5-1 | 2015-06-05 | 2015-06-08 | $40.08 | $200K | N/A | N/A | N/A |
| AAVL | SELL · 10b5-1 | 2015-05-19 | 2015-05-21 | $36.91 | $37K | N/A | N/A | N/A |
| [AAVL] | SELL · 10b5-1 | 2015-05-15 | 2015-05-18 | $35.49 | $798K | N/A | N/A | N/A |
| [AAVL] | SELL · 10b5-1 | 2015-05-13 | 2015-05-13 | $34.94 | $25K | N/A | N/A | N/A |
| [AAVL] | SELL · 10b5-1 | 2015-05-11 | 2015-05-12 | $34.91 | $62K | N/A | N/A | N/A |
| AAVL | SELL · 10b5-1 | 2015-05-01 | 2015-05-05 | $32.37 | $647K | N/A | N/A | N/A |
| AAVL | SELL · 10b5-1 | 2015-04-16 | 2015-04-20 | $41.59 | $1.0M | N/A | N/A | N/A |
| AAVL | SELL · 10b5-1 | 2015-04-07 | 2015-04-08 | $38.73 | $1.0M | N/A | N/A | N/A |
| AAVL | SELL | 2015-01-13 | 2015-01-15 | $55.46 | $5.5M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.